|
|
|
Insider
Information: |
Aryeh Jason |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
401,047 |
|
Indirect Shares
|
890,847 |
|
|
Direct
Value |
$7,148,144 |
|
|
Indirect Value
|
$4,945,268 |
|
|
Total
Shares |
1,291,894 |
|
|
Total
Value |
$12,093,412 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ligand Pharmaceuticals Inc |
LGND |
Director |
2024-04-30 |
76,828 |
2024-04-30 |
56,619 |
Premium* |
|
Vaxart Inc |
VXRT |
Director |
2010-12-27 |
0 |
2011-03-15 |
131,783 |
Premium* |
|
Myrexis Inc |
MYRX |
Director |
|
0 |
2012-06-15 |
552,145 |
Premium* |
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-05-15 |
242,433 |
2017-05-15 |
150,300 |
Premium* |
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Director |
2017-05-23 |
15,000 |
2017-05-23 |
0 |
Premium* |
|
Merrimack Pharmaceuticals Inc |
MACK |
See Explanation of Res... |
2019-07-16 |
3,802 |
2019-07-11 |
0 |
Premium* |
|
Orchestra BioMed Holdings Inc. |
OBIO |
Director |
2023-04-12 |
62,984 |
2023-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2018-08-17 |
4 |
S |
$241.81 |
$6,495,559 |
I/I |
(26,862) |
51,392 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2017-11-17 |
4 |
S |
$140.22 |
$3,421,368 |
I/I |
(24,400) |
90,251 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
INSIDER |
|
2014-02-18 |
144 |
NP |
$0.00 |
$3,091,664 |
/ |
40,320 |
0 |
|
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2017-02-27 |
4 |
S |
$106.00 |
$2,650,000 |
I/I |
(25,000) |
160,898 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2017-05-11 |
4 |
S |
$110.04 |
$2,494,025 |
I/I |
(22,665) |
131,233 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
Director |
|
2016-11-29 |
4 |
A |
$1.76 |
$1,999,999 |
D/D |
1,136,363 |
1,210,363 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2014-02-12 |
4 |
S |
$75.21 |
$1,814,121 |
I/I |
(24,120) |
260,916 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2016-05-06 |
4 |
S |
$118.52 |
$1,777,833 |
I/I |
(15,000) |
210,707 |
0 |
- |
|
ARLZ |
Aralez Pharmaceuticals In... |
Director |
|
2016-09-16 |
4 |
B |
$5.86 |
$1,732,664 |
I/I |
295,929 |
343,216 |
2.1 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2017-05-12 |
4 |
S |
$111.87 |
$1,631,334 |
I/I |
(14,582) |
116,651 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2016-11-22 |
4 |
S |
$107.40 |
$1,611,065 |
I/I |
(15,001) |
189,376 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2016-05-05 |
4 |
S |
$120.21 |
$1,202,121 |
I/I |
(10,000) |
225,707 |
0 |
- |
|
VXRT |
Vaxart Inc |
Director |
|
2009-11-16 |
4 |
S |
$4.49 |
$1,151,308 |
I/I |
(255,276) |
977,374 |
0 |
- |
|
VXRT |
Vaxart Inc |
Director |
|
2010-03-11 |
4 |
AS |
$5.88 |
$1,062,335 |
I/I |
(180,700) |
387,420 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
Director |
|
2015-06-16 |
4 |
B |
$3.47 |
$999,360 |
I/I |
288,000 |
288,000 |
2.1 |
- |
|
VXRT |
Vaxart Inc |
Director |
|
2009-11-17 |
4 |
S |
$4.64 |
$941,934 |
I/I |
(185,909) |
791,465 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2017-02-28 |
4 |
S |
$107.58 |
$753,060 |
I/I |
(7,000) |
153,898 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2014-02-14 |
4 |
S |
$78.87 |
$749,265 |
I/I |
(9,500) |
244,716 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2018-03-09 |
4 |
S |
$176.47 |
$705,899 |
I/I |
(4,000) |
79,334 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2018-03-08 |
4 |
S |
$174.88 |
$612,095 |
I/I |
(3,500) |
83,334 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2016-03-07 |
4 |
S |
$101.07 |
$568,895 |
I/I |
(5,629) |
236,207 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2018-02-23 |
4 |
S |
$155.00 |
$529,635 |
I/I |
(3,417) |
86,834 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2016-11-18 |
4 |
S |
$105.00 |
$525,000 |
I/I |
(5,000) |
204,377 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2015-05-18 |
4 |
S |
$86.74 |
$520,440 |
I/I |
(6,000) |
249,716 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Director |
|
2014-02-13 |
4 |
S |
$77.43 |
$518,779 |
I/I |
(6,700) |
254,216 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|